| __timestamp | Alkermes plc | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 49315000 |
| Thursday, January 1, 2015 | 311558000 | 75043000 |
| Friday, January 1, 2016 | 374130000 | 83749000 |
| Sunday, January 1, 2017 | 421578000 | 122682000 |
| Monday, January 1, 2018 | 526408000 | 207761000 |
| Tuesday, January 1, 2019 | 599449000 | 284812000 |
| Wednesday, January 1, 2020 | 538827000 | 317875000 |
| Friday, January 1, 2021 | 560977000 | 282660000 |
| Saturday, January 1, 2022 | 605747000 | 451421000 |
| Sunday, January 1, 2023 | 689751000 | 481871000 |
| Monday, January 1, 2024 | 645238000 |
Unleashing insights
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, from 2014 to 2023, Alkermes plc and Sarepta Therapeutics, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Alkermes has consistently outpaced Sarepta, with its SG&A expenses growing by approximately 245% from 2014 to 2023. In contrast, Sarepta's expenses surged by nearly 878% during the same period, reflecting its aggressive expansion strategy.
This analysis underscores the dynamic nature of biotech firms' operational strategies, offering a glimpse into their financial priorities.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs Alkermes plc
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Alkermes plc Trends and Insights
Who Optimizes SG&A Costs Better? Alkermes plc or Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Alkermes plc and Amicus Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Alkermes plc or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Alkermes plc vs Veracyte, Inc. Trends and Insights